260 related articles for article (PubMed ID: 11735161)
41. Arsenic trioxide: new preparation. Acute promyelocytic leukaemia: encouraging results but persistent doubts.
Prescrire Int; 2004 Aug; 13(72):135-7. PubMed ID: 15532137
[TBL] [Abstract][Full Text] [Related]
42. [Advances in the study on antineoplastic action of realgar].
Pan B; Xu L; Yang X
Zhong Yao Cai; 2004 Mar; 27(3):226-9. PubMed ID: 15346589
[No Abstract] [Full Text] [Related]
43. Co-biomodulation with arsenic trioxide in multiple myeloma.
Gallagher RE
Leuk Res; 2001 Mar; 25(3):237-9. PubMed ID: 11226520
[No Abstract] [Full Text] [Related]
44. What is the role of arsenic in newly diagnosed APL?
Tallman MS
Best Pract Res Clin Haematol; 2008 Dec; 21(4):659-66. PubMed ID: 19041605
[TBL] [Abstract][Full Text] [Related]
45. Solid tumors subsequent to arsenic trioxide treatment for acute promyelocytic leukemia.
Au WY; Kumana CR; Lam CW; Cheng VC; Shek TW; Chan EY; Liu R; Kwong YL
Leuk Res; 2007 Jan; 31(1):105-8. PubMed ID: 16725199
[TBL] [Abstract][Full Text] [Related]
46. Arsenic trioxide: new uses for an old remedy.
Belcastro PF
J Am Pharm Assoc (Wash); 2001; 41(3):366. PubMed ID: 11372896
[No Abstract] [Full Text] [Related]
47. Arsenic trioxide - An old drug rediscovered.
Emadi A; Gore SD
Blood Rev; 2010; 24(4-5):191-9. PubMed ID: 20471733
[TBL] [Abstract][Full Text] [Related]
48. All-trans-retinoic acid and arsenic trioxide as initial therapy for acute promyelocytic leukemia.
Quezada G; Kopp L; Estey E; Wells RJ
Pediatr Blood Cancer; 2008 Jul; 51(1):133-5. PubMed ID: 18293388
[TBL] [Abstract][Full Text] [Related]
49. Superiority of an arsenic trioxide-based regimen over a historic control combining all-trans retinoic acid plus intensive chemotherapy in the treatment of relapsed acute promyelocytic leukemia.
Thomas X; Pigneux A; Raffoux E; Huguet F; Caillot D; Fenaux P
Haematologica; 2006 Jul; 91(7):996-7. PubMed ID: 16757416
[TBL] [Abstract][Full Text] [Related]
50. Arsenic trioxide for the treatment of acute promyelocytic leukemia.
Lam MS; Ignoffo RJ
Cancer Pract; 2001; 9(3):155-7. PubMed ID: 11879303
[No Abstract] [Full Text] [Related]
51. Effect of arsenic trioxide on QT interval in patients with advanced malignancies.
Barbey JT; Pezzullo JC; Soignet SL
J Clin Oncol; 2003 Oct; 21(19):3609-15. PubMed ID: 14512391
[TBL] [Abstract][Full Text] [Related]
52. Arsenic trioxide in the treatment of relapsed and refractory acute promyelocytic leukemia.
Asou N
Intern Med; 2005 Aug; 44(8):775-6. PubMed ID: 16157968
[No Abstract] [Full Text] [Related]
53. Arsenic trioxide mechanisms of action--looking beyond acute promyelocytic leukemia.
Carney DA
Leuk Lymphoma; 2008 Oct; 49(10):1846-51. PubMed ID: 18949607
[No Abstract] [Full Text] [Related]
54. Arsenic trioxide for the treatment of a relapsed acute promyelocytic leukemia with acute renal failure.
Yoon HS; Park TS; Jeong KH
Pediatr Blood Cancer; 2011 Dec; 57(6):1085. PubMed ID: 21656902
[No Abstract] [Full Text] [Related]
55. [Clinical observation and follow-up study on acute promyelocytic leukemia in childhood treated mainly with arsenic trioxide].
Hao LC; Wang H; Zhang LZ
Zhonghua Er Ke Za Zhi; 2005 Jul; 43(7):534-5. PubMed ID: 16083560
[No Abstract] [Full Text] [Related]
56. A single course of all-trans retinoic acid plus arsenic trioxide reached a long-term survival in a patient with newly diagnosed acute promyelocytic leukemia: a suggestion for reduction of treatment courses?
Yan J; Chen X; Shao J
Eur J Haematol; 2013 Nov; 91(5):470-1. PubMed ID: 23869721
[No Abstract] [Full Text] [Related]
57. Role of GSTP1-1 in mediating the effect of As2O3 in the Acute Promyelocytic Leukemia cell line NB4.
Bernardini S; Nuccetelli M; Noguera NI; Bellincampi L; Lunghi P; Bonati A; Mann K; Miller WH; Federici G; Lo Coco F
Ann Hematol; 2006 Oct; 85(10):681-7. PubMed ID: 16733740
[TBL] [Abstract][Full Text] [Related]
58. [Progresses in the study of hematology in China, 1997].
Zhang Z
Zhonghua Yi Xue Za Zhi; 1997 Dec; 77(12):890-1. PubMed ID: 9772548
[No Abstract] [Full Text] [Related]
59. Anion exchanger 2 mediates the action of arsenic trioxide.
Pan XY; Chen GQ; Cai L; Buscemi S; Fu GH
Br J Haematol; 2006 Sep; 134(5):491-9. PubMed ID: 17018029
[TBL] [Abstract][Full Text] [Related]
60. Use of arsenic trioxide as a first-line single agent in the treatment of acute promyelocytic leukemia.
Keyhani M
J Clin Oncol; 2012 Jan; 30(2):217; author reply 218-20; discussion 220-2. PubMed ID: 22124099
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]